Raymond James lowered the firm’s price target on Procter & Gamble to $185 from $190 and keeps an Outperform rating on the shares. Sales moderation led to mixed Q3 results, and the FY25 outlook was lowered to below what the market was expected, the analyst tells investors in a research note. The firm believes P&G is better positioned than in the past to navigate the current choppy waters.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PG:
- Procter & Gamble price target lowered to $175 from $189 at TD Cowen
- Procter & Gamble price target lowered to $175 from $185 at Wells Fargo
- Procter & Gamble: Long-Term Growth Potential Amid Short-Term Challenges Justifies Buy Rating
- Procter & Gamble price target lowered to $181 from $200 at Citi
- Procter & Gamble price target lowered to $180 from $190 at BofA